LONDON, April 29 (Reuters) – Prime Minister Keir Starmer said on Wednesday that Britain’s biggest company \u200cAstraZeneca would invest 300 million pounds ($405 million) \u200cin the country, after pausing large-scale projects last year.<\/p>\n
“I can \u200bannounce a significant new investment by AstraZeneca, investing 300 million pounds in UK life sciences, made possible by the pharmaceutical arrangement we have struck with \u200cthe United States,” \u2060Starmer told lawmakers in parliament.<\/p>\n
The investment comes after drugmakers, including AstraZeneca, have praised \u2060the U.S.-UK deal, which is aimed at increasing medicine prices in Britain, in line with the \u200bTrump administration’s \u200bnew U.S. pricing policies.<\/p>\n
Companies, \u200bincluding AstraZeneca, say Europe \u200crisks missing out on new medicines in the new policy environment, known as most-favored-nations.<\/p>\n
AstraZeneca had pulled back projects in Britain, citing the business environment, including a 200-million-pound investment plan in Cambridge where \u200cit has one of the \u200bcountry’s leading life sciences hubs. \u200bIt had earlier \u200bscrapped a proposed 450-million-pound in a \u200cvaccine manufacturing plant in northern \u200bEngland after \u200ba cut in government support.<\/p>\n
Starmer said the latest investment would future proof 1,000 jobs in \u200bthe northern \u200cEnglish town of Macclesfield and in Cambridge.<\/p>\n
($1 = 0.7405 \u200bpounds)<\/p>\n
(Reporting by Sam Tobin and Sam Tabahriti; \u200bEditing by Muvija M)<\/p>\n","protected":false},"excerpt":{"rendered":"LONDON, April 29 (Reuters) – Prime Minister Keir Starmer said on Wednesday that Britain’s biggest company \u200cAstraZeneca would…\n","protected":false},"author":2,"featured_media":24858,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[2],"tags":[11153,13,371,94],"class_list":{"0":"post-24857","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-britain","8":"tag-astrazeneca","9":"tag-britain","10":"tag-investment","11":"tag-keir-starmer"},"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@UnitedKingdom\/116487900702117051","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/britain\/wp-json\/wp\/v2\/posts\/24857","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/britain\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/britain\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/britain\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/britain\/wp-json\/wp\/v2\/comments?post=24857"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/britain\/wp-json\/wp\/v2\/posts\/24857\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/britain\/wp-json\/wp\/v2\/media\/24858"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/britain\/wp-json\/wp\/v2\/media?parent=24857"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/britain\/wp-json\/wp\/v2\/categories?post=24857"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/britain\/wp-json\/wp\/v2\/tags?post=24857"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}